A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1995-05

AUTHORS

Helen W. Pass, Barbara K. Temeck, Karen Kranda, Seth M. Steinberg, Harvey I. Pass

ABSTRACT

Background: The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. We initiated a phase II trial of immunochemotherapy with cisplatinum (25 mg/m2 four times weekly), interferon-α (5 mU/m2 s.c. three times weekly), and tamoxifen (20 mg orally twice a day for 35 days) (CIT) based on in vitro and in vivo data suggesting interrelating efficacy of this combination.Methods: Since July 1991, 36 patients have been evaluable for response after receiving one to five cycles of CIT. Ten additional patients had debulking surgery followed by two cycles of postoperative adjuvant CIT commencing a mean of 6 weeks after surgery.Results: Toxicity was acceptable (4% grade III/IV). One treatment-related death (2%) occurred, from myocardial infarction. A 19% partial response rate, objectively quantified using three-dimensional computerized tomographic (CT) measurement of solid disease volume, was recorded. The median survival for the seven responders was 14.7 months, whereas that of the nonresponders was 8 months (p2=0.2). Median survival for the entire group was 8.7 months. Preoperative size, platelet count >360,000/ml, and nonepithelial histology were associated with shortened survival.Conclusions: The CIT regimen has some activity in MPM and can be delivered after debulking resection. In good-risk patients, as defined by favorable prognostic factors, a randomized trial using this combination may be warranted. More... »

PAGES

214-220

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf02307026

DOI

http://dx.doi.org/10.1007/bf02307026

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018395434

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/7641017


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Feasibility Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Interferon-alpha", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mesothelioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pleural Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pass", 
        "givenName": "Helen W.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Temeck", 
        "givenName": "Barbara K.", 
        "id": "sg:person.01306041342.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kranda", 
        "givenName": "Karen", 
        "id": "sg:person.01032321717.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA", 
          "id": "http://www.grid.ac/institutes/grid.94365.3d", 
          "name": [
            "the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steinberg", 
        "givenName": "Seth M.", 
        "id": "sg:person.014210640617.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA", 
          "id": "http://www.grid.ac/institutes/grid.48336.3a", 
          "name": [
            "Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pass", 
        "givenName": "Harvey I.", 
        "id": "sg:person.0763326335.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00194542", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052242345", 
          "https://doi.org/10.1007/bf00194542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00255753", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040954660", 
          "https://doi.org/10.1007/bf00255753"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1995-05", 
    "datePublishedReg": "1995-05-01", 
    "description": "Background: The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. We initiated a phase II trial of immunochemotherapy with cisplatinum (25 mg/m2 four times weekly), interferon-\u03b1 (5 mU/m2 s.c. three times weekly), and tamoxifen (20 mg orally twice a day for 35 days) (CIT) based on in vitro and in vivo data suggesting interrelating efficacy of this combination.Methods: Since July 1991, 36 patients have been evaluable for response after receiving one to five cycles of CIT. Ten additional patients had debulking surgery followed by two cycles of postoperative adjuvant CIT commencing a mean of 6 weeks after surgery.Results: Toxicity was acceptable (4% grade III/IV). One treatment-related death (2%) occurred, from myocardial infarction. A 19% partial response rate, objectively quantified using three-dimensional computerized tomographic (CT) measurement of solid disease volume, was recorded. The median survival for the seven responders was 14.7 months, whereas that of the nonresponders was 8 months (p2=0.2). Median survival for the entire group was 8.7 months. Preoperative size, platelet count >360,000/ml, and nonepithelial histology were associated with shortened survival.Conclusions: The CIT regimen has some activity in MPM and can be delivered after debulking resection. In good-risk patients, as defined by favorable prognostic factors, a randomized trial using this combination may be warranted.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf02307026", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1105545", 
        "issn": [
          "1068-9265", 
          "1534-4681"
        ], 
        "name": "Annals of Surgical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "malignant pleural mesothelioma", 
      "phase II trial", 
      "median survival", 
      "pleural mesothelioma", 
      "treatment-related deaths", 
      "good-risk patients", 
      "partial response rate", 
      "favorable prognostic factor", 
      "computerized tomographic measurements", 
      "nonepithelial histology", 
      "adjuvant immunochemotherapy", 
      "maximal cytoreduction", 
      "prognostic factors", 
      "additional patients", 
      "disease volume", 
      "preoperative size", 
      "platelet count", 
      "myocardial infarction", 
      "response rate", 
      "immunochemotherapy", 
      "entire group", 
      "surgery", 
      "patients", 
      "trials", 
      "months", 
      "mesothelioma", 
      "survival", 
      "vivo data", 
      "standard techniques", 
      "tomographic measurements", 
      "cytoreduction", 
      "nonresponders", 
      "regimen", 
      "resection", 
      "infarction", 
      "chemotherapy", 
      "cisplatinum", 
      "tamoxifen", 
      "radiotherapy", 
      "CIT", 
      "interferon", 
      "responders", 
      "histology", 
      "weeks", 
      "efficacy", 
      "death", 
      "treatment", 
      "toxicity", 
      "counts", 
      "group", 
      "response", 
      "combination", 
      "factors", 
      "activity", 
      "rate", 
      "volume", 
      "cycle", 
      "use", 
      "data", 
      "feasibility", 
      "means", 
      "technique", 
      "size", 
      "measurements", 
      "II trial", 
      "cycles of CIT", 
      "postoperative adjuvant CIT", 
      "adjuvant CIT", 
      "three-dimensional computerized tomographic (CT) measurement", 
      "solid disease volume", 
      "CIT regimen", 
      "primary immunochemotherapy"
    ], 
    "name": "A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction", 
    "pagination": "214-220", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018395434"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf02307026"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "7641017"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf02307026", 
      "https://app.dimensions.ai/details/publication/pub.1018395434"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:09", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_280.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf02307026"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf02307026'


 

This table displays all metadata directly associated to this object as RDF triples.

240 TRIPLES      22 PREDICATES      118 URIs      108 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf02307026 schema:about N0033456b41cd409aa490120cf9a3cd5b
2 N08f29986beb34f0fbc50da15906315c3
3 N1dffaac00ab54017902fc469004dc8f8
4 N282fdecb16bf47e1b612d0a9911eff20
5 N4c0624998929453f9c5413347b7493b5
6 N7d25548c5f6c4bc198dde64ca4e372d0
7 N7f956bf7987441cebdbfd3224cc0564a
8 N822c7574e03f44b981e659435292e2b5
9 N89df0af2bb07472aad41c6ef390397ef
10 Naec087505d744b1bb7f5e8b4a7f17760
11 Nb074d08905f14773b0f630b9bb063d33
12 Nbf24b0ccf7404375ace0e28e1a711315
13 Nc97f0ce6bbf84f5284506a8d3b231398
14 Nd73f53fdcf6d4d438967eb3167b117c1
15 Nd9bc3680b5b1464a85c45e70e4ccaab4
16 Nd9d539b0667e4e669fb6ae645e8169a1
17 Nf824414d0de64e649eb7c7f6cedc2bf3
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author N42e70b8725a549e6a4fc06e600609a60
21 schema:citation sg:pub.10.1007/bf00194542
22 sg:pub.10.1007/bf00255753
23 schema:datePublished 1995-05
24 schema:datePublishedReg 1995-05-01
25 schema:description Background: The treatment of malignant pleural mesothelioma (MPM) continues to be inadequate with the use of standard techniques, including surgery, radiotherapy and chemotherapy. We initiated a phase II trial of immunochemotherapy with cisplatinum (25 mg/m2 four times weekly), interferon-α (5 mU/m2 s.c. three times weekly), and tamoxifen (20 mg orally twice a day for 35 days) (CIT) based on in vitro and in vivo data suggesting interrelating efficacy of this combination.Methods: Since July 1991, 36 patients have been evaluable for response after receiving one to five cycles of CIT. Ten additional patients had debulking surgery followed by two cycles of postoperative adjuvant CIT commencing a mean of 6 weeks after surgery.Results: Toxicity was acceptable (4% grade III/IV). One treatment-related death (2%) occurred, from myocardial infarction. A 19% partial response rate, objectively quantified using three-dimensional computerized tomographic (CT) measurement of solid disease volume, was recorded. The median survival for the seven responders was 14.7 months, whereas that of the nonresponders was 8 months (p2=0.2). Median survival for the entire group was 8.7 months. Preoperative size, platelet count >360,000/ml, and nonepithelial histology were associated with shortened survival.Conclusions: The CIT regimen has some activity in MPM and can be delivered after debulking resection. In good-risk patients, as defined by favorable prognostic factors, a randomized trial using this combination may be warranted.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree false
29 schema:isPartOf N526ca0d63a394da2befcb40ac3e1e23e
30 Ne766859beaae4e1c9428d098c71deb8f
31 sg:journal.1105545
32 schema:keywords CIT
33 CIT regimen
34 II trial
35 activity
36 additional patients
37 adjuvant CIT
38 adjuvant immunochemotherapy
39 chemotherapy
40 cisplatinum
41 combination
42 computerized tomographic measurements
43 counts
44 cycle
45 cycles of CIT
46 cytoreduction
47 data
48 death
49 disease volume
50 efficacy
51 entire group
52 factors
53 favorable prognostic factor
54 feasibility
55 good-risk patients
56 group
57 histology
58 immunochemotherapy
59 infarction
60 interferon
61 malignant pleural mesothelioma
62 maximal cytoreduction
63 means
64 measurements
65 median survival
66 mesothelioma
67 months
68 myocardial infarction
69 nonepithelial histology
70 nonresponders
71 partial response rate
72 patients
73 phase II trial
74 platelet count
75 pleural mesothelioma
76 postoperative adjuvant CIT
77 preoperative size
78 primary immunochemotherapy
79 prognostic factors
80 radiotherapy
81 rate
82 regimen
83 resection
84 responders
85 response
86 response rate
87 size
88 solid disease volume
89 standard techniques
90 surgery
91 survival
92 tamoxifen
93 technique
94 three-dimensional computerized tomographic (CT) measurement
95 tomographic measurements
96 toxicity
97 treatment
98 treatment-related deaths
99 trials
100 use
101 vivo data
102 volume
103 weeks
104 schema:name A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction
105 schema:pagination 214-220
106 schema:productId Na4be0dfaac844a578585d1a01d548870
107 Nd76f3b3028004e65a1f20dc596123bfd
108 Ndc967a64423645e8a49d8eae314c31e3
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018395434
110 https://doi.org/10.1007/bf02307026
111 schema:sdDatePublished 2021-12-01T19:09
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Nbde4eccdd9024a9380553fa518fb5c95
114 schema:url https://doi.org/10.1007/bf02307026
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N0033456b41cd409aa490120cf9a3cd5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Aged
120 rdf:type schema:DefinedTerm
121 N08f29986beb34f0fbc50da15906315c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Middle Aged
123 rdf:type schema:DefinedTerm
124 N1dffaac00ab54017902fc469004dc8f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Female
126 rdf:type schema:DefinedTerm
127 N226fa2fab0ac4570bb26dc36e39da1d0 rdf:first sg:person.014210640617.24
128 rdf:rest Ndee21d0c029a470ba57249aba071cf88
129 N282fdecb16bf47e1b612d0a9911eff20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Immunotherapy
131 rdf:type schema:DefinedTerm
132 N2a46afccafb2477595ca5c952638ca2d rdf:first sg:person.01032321717.09
133 rdf:rest N226fa2fab0ac4570bb26dc36e39da1d0
134 N42e70b8725a549e6a4fc06e600609a60 rdf:first Neafa9643d6a14d4db765db309fc33491
135 rdf:rest N4bfd59b3b7124fdea58c8ab7b9b699f4
136 N4bfd59b3b7124fdea58c8ab7b9b699f4 rdf:first sg:person.01306041342.14
137 rdf:rest N2a46afccafb2477595ca5c952638ca2d
138 N4c0624998929453f9c5413347b7493b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cisplatin
140 rdf:type schema:DefinedTerm
141 N526ca0d63a394da2befcb40ac3e1e23e schema:issueNumber 3
142 rdf:type schema:PublicationIssue
143 N7d25548c5f6c4bc198dde64ca4e372d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Pleural Neoplasms
145 rdf:type schema:DefinedTerm
146 N7f956bf7987441cebdbfd3224cc0564a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Tamoxifen
148 rdf:type schema:DefinedTerm
149 N822c7574e03f44b981e659435292e2b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Humans
151 rdf:type schema:DefinedTerm
152 N89df0af2bb07472aad41c6ef390397ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Feasibility Studies
154 rdf:type schema:DefinedTerm
155 Na4be0dfaac844a578585d1a01d548870 schema:name dimensions_id
156 schema:value pub.1018395434
157 rdf:type schema:PropertyValue
158 Naec087505d744b1bb7f5e8b4a7f17760 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Mesothelioma
160 rdf:type schema:DefinedTerm
161 Nb074d08905f14773b0f630b9bb063d33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Proportional Hazards Models
163 rdf:type schema:DefinedTerm
164 Nbde4eccdd9024a9380553fa518fb5c95 schema:name Springer Nature - SN SciGraph project
165 rdf:type schema:Organization
166 Nbf24b0ccf7404375ace0e28e1a711315 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Chemotherapy, Adjuvant
168 rdf:type schema:DefinedTerm
169 Nc97f0ce6bbf84f5284506a8d3b231398 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Survival Analysis
171 rdf:type schema:DefinedTerm
172 Nd73f53fdcf6d4d438967eb3167b117c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Treatment Outcome
174 rdf:type schema:DefinedTerm
175 Nd76f3b3028004e65a1f20dc596123bfd schema:name doi
176 schema:value 10.1007/bf02307026
177 rdf:type schema:PropertyValue
178 Nd9bc3680b5b1464a85c45e70e4ccaab4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Adult
180 rdf:type schema:DefinedTerm
181 Nd9d539b0667e4e669fb6ae645e8169a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Interferon-alpha
183 rdf:type schema:DefinedTerm
184 Ndc967a64423645e8a49d8eae314c31e3 schema:name pubmed_id
185 schema:value 7641017
186 rdf:type schema:PropertyValue
187 Ndee21d0c029a470ba57249aba071cf88 rdf:first sg:person.0763326335.92
188 rdf:rest rdf:nil
189 Ne766859beaae4e1c9428d098c71deb8f schema:volumeNumber 2
190 rdf:type schema:PublicationVolume
191 Neafa9643d6a14d4db765db309fc33491 schema:affiliation grid-institutes:grid.48336.3a
192 schema:familyName Pass
193 schema:givenName Helen W.
194 rdf:type schema:Person
195 Nf824414d0de64e649eb7c7f6cedc2bf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Male
197 rdf:type schema:DefinedTerm
198 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
199 schema:name Medical and Health Sciences
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
202 schema:name Oncology and Carcinogenesis
203 rdf:type schema:DefinedTerm
204 sg:journal.1105545 schema:issn 1068-9265
205 1534-4681
206 schema:name Annals of Surgical Oncology
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.01032321717.09 schema:affiliation grid-institutes:grid.48336.3a
210 schema:familyName Kranda
211 schema:givenName Karen
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032321717.09
213 rdf:type schema:Person
214 sg:person.01306041342.14 schema:affiliation grid-institutes:grid.48336.3a
215 schema:familyName Temeck
216 schema:givenName Barbara K.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306041342.14
218 rdf:type schema:Person
219 sg:person.014210640617.24 schema:affiliation grid-institutes:grid.94365.3d
220 schema:familyName Steinberg
221 schema:givenName Seth M.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014210640617.24
223 rdf:type schema:Person
224 sg:person.0763326335.92 schema:affiliation grid-institutes:grid.48336.3a
225 schema:familyName Pass
226 schema:givenName Harvey I.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763326335.92
228 rdf:type schema:Person
229 sg:pub.10.1007/bf00194542 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052242345
230 https://doi.org/10.1007/bf00194542
231 rdf:type schema:CreativeWork
232 sg:pub.10.1007/bf00255753 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040954660
233 https://doi.org/10.1007/bf00255753
234 rdf:type schema:CreativeWork
235 grid-institutes:grid.48336.3a schema:alternateName Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA
236 schema:name Thoracic Oncology Section, Surgery Branch, NCI/NIH, Building 10, Room 2B07, 20892, Bethesda, MD, USA
237 rdf:type schema:Organization
238 grid-institutes:grid.94365.3d schema:alternateName the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
239 schema:name the Biostatistics and Data Management Section, National Institutes of Health, Bethesda, Maryland, USA
240 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...